Abstract
BackgroundAlthough there are increasing evidences of lncRNA role in cancer progression, and of its possible diagnostic and therapeutic significance, lncRNA in thyroid neoplasms are poorly investigated: studies are limited to papillary cancer, the differences in variants of papillary carcinoma are rarely considered, there are no investigations of lncRNA in benign nodules, follicular and anaplastic carcinomas. MethodsTo evaluate lncRNA expression in follicular adenoma (FA), follicular and classical variants of papillary carcinoma (fvPTC/clPTC), follicular (FTC) and anaplastic (ATC) carcinomas, a comprehensive dataset of 8 independent Microarray experiments on Affymetrix Human Genome U133 Plus 2.0 Array and RNA-Seq experiments (TCGA and PRJEB11591 projects) was analyzed. In silico validation of differential expression was performed. Putative functions of aberrantly expressed lncRNA were determined via co-expression and enrichment analysis of Gene Ontology, KEGG, Reactome terms. ResultsThe analysis revealed 8 lncRNA general for all investigated neoplasms, 22 - general for papillary carcinomas, 32 - specific for clPTC, 1 - for fvPTC, and 177 - specific for ATC. No lncRNA differentially expressed in FTC and FA was found. There are strong clustering of ATC, clustering of clPTC and fvPTC, no clustering within the FTC and FA. LncRNA found to be specific for ATC are probably associated with anaplastic features and cancer progression. Potential functions of lncRNA general for all studied neoplasms - L1CAM interactions; general for papillary carcinomas - tryptophan metabolism; specific for fvPTC - cell polarity and WNT signaling; specific for clPTC - extracellular matrix organization and endoderm formation; specific for ATC - cell cycle and mitosis. Known oncogenic and tumor suppressor lncRNA (NR2F1-AS1, LINC00511, SLC26A4-AS1, CRNDE, LINC01116, RMST) are found in thyroid carcinomas for the first time. ConclusionsCommon and specific patterns of lncRNA expression in main histological subtypes of thyroid nodules are determined. The findings enhance the understanding of lncRNA in thyroid cancer progression. Legal entity responsible for the studyThe authors. FundingHas not received any funding. DisclosureAll authors have declared no conflicts of interest.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.